AG Coffman Joins Lawsuit Against Generic Drug Companies who Allegedly Conspired to Inflate and Manipulate Generic Medication Prices | Attorney General - State of Colorado

AG Coffman Joins Lawsuit Against Generic Drug Companies who Allegedly Conspired to Inflate and Manipulate Generic Medication Prices

Attorney General Cynthia H. Coffman announced today that Colorado has joined a federal antitrust lawsuit alleging that six generic drug-makers—Heritage  Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., Citron Pharma, LLC, Mayne Pharma (USA), Inc., Mylan Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.—conspired to artificially inflate and manipulate prices for two generic drugs.

“Colorado consumers depend on generic drugs to provide low-cost options for the medications they need,” said Attorney General Coffman. “This type of blatantly anticompetitive conduct harms Coloradans and my office will continue to hold these companies accountable.” 

Colorado joined the multi-state case with an amended complaint filed in federal court in Connecticut. The complaint alleges that the defendants routinely coordinated with their competitors in a long-running conspiracy to fix prices and allocate markets for doxycycline hyclate delayed release, an antibiotic, and glyburide, an oral diabetes medication. According to the complaint, defendants perpetuated this illegal conspiracy through communications at industry trade shows, customer conferences and other events, as well as through direct email, phone and text message communications. The alleged anticompetitive conduct – including efforts to fix and maintain prices, allocate markets and otherwise thwart competition – caused significant, harmful and continuing effects on the country’s healthcare system, the states charge.

The original complaint was filed in December of 2016, and has grown to include 40 states.  The amended complaint also adds claims of alleged violations of state law in addition to the alleged violations of federal antitrust laws against the defendant generic companies.

Portions of the attached complaint are redacted in order to avoid compromising an ongoing investigation of similar anticompetitive behavior related to additional generic drugs, generic drug companies and key executives.